Non-SELEX: Selection of aptamers without intermediate amplification of candidate oligonucleotides

Nature Protocols

Volumn 1, Issue 3, 2006, Pages 1359-1369

  Berezovski, Maxim V ^a,b   Musheev, Michael U ^a   Drabovich, Andrei P ^a   Jitkova, Julia V ^a,b   Krylov, Sergey N ^a  

^a YORK UNIVERSITY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER;

ARTICLE; CAPILLARY ELECTROPHORESIS; GENE LIBRARY; GENETIC PROCEDURES; METHODOLOGY;

APTAMERS, NUCLEOTIDE; ELECTROPHORESIS, CAPILLARY; GENE LIBRARY; GENETIC TECHNIQUES;

EID: 33846611331     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2006.200     Document Type: Article

References (48)

1. Wilson, D.S. & Szostak, J.W. In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 68, 611-647 (1999).
2. Famulok, M., Mayer, G. & Blind, M. Nucleic acid aptamers - from selection in vitro to applications in vivo. Acc. Chem. Res. 33, 591-599 (2000).
3. Rimmele, M. Nucleic acid aptamers as tools and drugs: Recent developments. Chembiochem 4, 963-971 (2003).
4. Jayasena, S.D. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45, 1628-1650 (1999).
5. Lee, J.F., Stovall, G.M. & Ellington, A.D. Aptamer therapeutics advance. Curr. Opin. Chem. Biol. 10, 282-289 (2006).
6. Bock, C. et al. Photoaptamer arrays applied to multiplexed proteomic analysis. Proteomics 4, 609-618 (2004).
7. Surugiu-Warnmark, I., Warnmark, A., Toresson, G., Gustafsson, J.A. & Bulow, L. Selection of DNA aptamers against rat Liver X receptors. Biochem. Biophys. Res. Commun. 332, 512-517 (2005).
8. Pestourie, C., Tavitian, B. & Duconge, F. Aptamers against extracellular targets for in vivo applications. Biochimie 87, 921-930 (2005).
9. Davidson, E.A. & Ellington, A.D. Engineering regulatory RNAs. Trends Biotechnol. 23, 109-112 (2005).
10. Mayer, G. & Jenne, A. Aptamers in research and drug development. BioDrugs 18, 351-359 (2004).
11. Nutiu, R., Yu, J.M. & Li, Y. Signaling aptamers for monitoring enzymatic activity and for inhibitor screening. Chembiochem 5, 1139-1144 (2004).
12. Famulok, M. & Mayer, G. Intramers and aptamers: Applications in protein-function analyses and potential for drug screening. Chembiochem 6, 19-26 (2005).
13. Ulrich, H., Martins, A.H. & Pesquero, J.B. RNA and DNA aptamers in cytomics analysis. Cytometry A 59, 220-231 (2004).
14. Stojanovic, M.N. & Kolpashchikov D.M. Modular aptameric sensors. J. Am. Chem. Soc. 126, 9266-9270 (2004).
15. Nimjee, S.M., Rusconi, C.P. & Sullenger, B.A. Aptamers: An emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
16. Patil, S.D., Rhodes, D.G. & Burgess, D.J. DNA-based therapeutics and DNA delivery systems: A comprehensive review. AAPS J. 7, 61-77 (2005).
17. Lee, J.F., Hesselberth, J.R., Meyers, L.A. & Ellington, A.D. Aptamer database. Nucleic Acids Res. 32, D95-D100 (2004).
18. Ellington, A. & Szostak, J. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822 (1990).
19. Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential. enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510 (1990).
20. O'Connell, D. et al. Calcium-dependent oligonucleotide antagonists against L-selectin. Proc. Natl. Acad. Sci. USA 93, 5883-5887 (1996).
21. Ulrich, H. et al. In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA 95, 14051-14056 (1998).
22. Burke, D.H., Scates, L., Andrews, K. & Gold, L. Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J. Mol. Biol. 264, 650-666 (1996).
23. Drolet, D.W., Jenison, R.D., Smith, D.E., Pratt, D. & Hicke, B. A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX). Comb. Chem. High Throughput Screen. 2, 271-278 (1999).
24. Beutel, B.A. & Gold, L. In vitro evolution of intrinsically bent DNA. J. Mol. Biol. 228, 803-812 (1992).
25. Ciesiolka, J. et al. Affinity selection-amplification from randomized ribooligonucloetide pools. Methods Enzymol. 267, 315-335 (1996).
26. Irvine, D., Tuerk, C. & Gold, L. SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis. J. Mol. Biol. 222, 739-761 (1991).
27. Vant-Hull, B., Antonio, P.-B., Davis, R.H. & Gold, L. The mathematics of SELEX against complex targets. J. Mol. Biol. 278, 579-597 (1998).
28. Schneider, D., Gold, L. & Platt, T. Selective enrichment of RNA species for tight binding to Escherichia coli rho factor. FASEB J. 7, 201-207 (1993).
29. Chen, H. & Gold, L. Selection of high-affinity RNA ligands to reverse transcriptase: Inhibition of cDNA synthesis and RNase H activity. Biochemistry 33, 8746-8756 (1994).
30. Tian, Y. et al. Dissecting protein:pRotein interactions between transcription factors with an RNA aptamer. RNA 1, 317-326 (1995).
31. Petrov, A., Okhonin, V., Berezovski, M. & Krylov, S.N. Kinetic capillary electrophoresis (KCE): A conceptual platform for kinetic homogeneous affinity methods. J. Am. Chem. Soc. 127, 17104-17110 (2005).
32. Heegaard, N.H.H. & Robey, F.A. Use of capillary zone electrophoresis to evaluate the binding of anionic carbohydrates to synthetic peptides derived from human serum amyloid P component. Anal. Chem. 64 2479-2482 (1992).
33. Chu,Y.H., Avila, L.Z., Biebuyck, H.A. & Whitesides, G.M. Use of affinity capillary electrophoresis to measure binding constants of ligands to proteins. J. Med. Chem. 35, 2915-2917 (1992).
34. Mendonsa, S.D. & Bowser, M.T. In vitro evolution of functional DNA using capillary electrophoresis. J. Am. Chem. Soc. 126 20-21 (2004).
35. Mosing, R.K., Mendonsa, S.D. & Bowser, M.T. Capillary electrophoresis-SELEX selection of aptamers with affinity for HIV-1 reverse transcriptase. Anal. Chem. 77, 6107-6112 (2005).
36. Berezovski, M. et al. Nonequilibrium capillequilibrium mixtures: A universal tool for development of aptamers. J. Am. Chem. Soc. 127, 3165-317l (2005).
37. Drabovich, A.P., Berezovski, M., Okhonin, V. & Krylov, S.N. Selection of smart aptamers by methods of kinetic capillary etectrophoresis. Anal. Chem. 78, 3171-3178 (2006).
38. Berezovski, M., Musheev, M., Drabovich, A. & Krylov, S.N. Non-SELEX selection of aptamers. J. Am. Chem. Soc. 128, 1410-1411 (2006).
39. Drabovich, A., Berezovski, M. & Krylov, S.N. Selection of smart aptamers by equilibrium capillary etectrophoresis of equilibrium mixtures (ECEEM). J. Am. Chem. Soc. 127, 11224-11225 (2005).
40. Berezovski, M. & Krylov, S.N. Nonequilibrium capillary electrophoresis of equilibrium mixtures - a single experiment reveals equilibrium and kinetic parameters of protein-DNA interactions. J. Am. Chem. Soc. 124, 13764-13765 (2002).
41. Berezovski, M. & Krylov, S.N. Thermochemistry of protein-DNA interaction studied with tempetature-controlled nonequilibrium capillary electrophoresis of equilibrium mixtures. Anal. Chem. 77, 1526-1529 (2005).
42. Thiel, K. Oligo oligarchy - the surprisingly small world of aptamers. Nat. Biotechnol. 22, 649-651 (2004).
43. Kanna, M.W., Rozenman, M.M., Sakurai, K., Snyder, T.M. & Liu, D.R. Reaction discovery enabled by DNA-templated synthesis and in vivo selection. Nature 431, 545-549 (2004).
44. Garner, Z.J. et al. DNA-templated synthesis and selection of a library of macrocycles. Science 305, 1601-1605 (2004).
45. Takahashi, T.T., Austin, R.J. & Roberts, R.W. mRNA display: Ligand discovery, interaction analysis and beyond. Trends Biochem. Sci. 28, 159-165 (2003).
46. Don, R.H., Cox, P.T., Wainwright, B.J., Baker, K. & Mattick, J.S. 'Touchdown' PCR to circumvent-spurious priming during gene amplification. Nucleic Acids Res. 19, 4008 (1991).
47. Musheev, M.U. & Krylov, S.N. Selection of aptamers by systematic evolution of ligands by exponential enrichment: Addressing the polymerase chain reaction issue. Anal. Chim. Acta. 564, 91-96 (2006).
48. Sanger, F., Nicklen, S. & Coulson, A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463-5471 (1977).